Physician-guided care in Florida and ColoradoFL (954) 953-3662  |  CO (720) 902-8247
Home / Guides / GLP-1 Medications and Alcohol: What Labels and Studies Say

GLP-1 Medications and Alcohol: What Labels and Studies Say

Wegovy and Zepbound labels give no drinking guidance, but they flag dehydration, low blood sugar and pancreatitis. Early trials on drinking are small.

Before and after photo of a Healthy Weight Loss 4 U patient; individual results vary
Real Healthy Weight Loss 4 U patient photo. Individual results vary and are not guaranteed.

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 20, 2026 · Updated October 20, 2026 · 9 min read

In short

The Wegovy and Zepbound labels contain no instructions about drinking alcohol, but both warn about dehydration from vomiting or diarrhea, pancreatitis, and (with diabetes drugs) low blood sugar [1][2]. Two randomized trials, of 48 and 108 adults, found less heavy drinking on semaglutide, yet no GLP-1 medicine is approved for alcohol use disorder [3][4][8].

Key takeaways

  • The Zepbound label (revised 04/2026) uses the word alcohol only for benzyl alcohol, an inactive ingredient; it has no drinking guidance [1].
  • Nausea occurred in 44% of adults on Wegovy versus 16% on placebo, and vomiting in 24% versus 6%, so GI illness plus dehydration is a labeled concern [2].
  • With a sulfonylurea, Zepbound users had hypoglycemia in 10.3% versus 2.1% without one in a type 2 diabetes trial [1].
  • A 9-week randomized trial of 48 adults found semaglutide cut alcohol consumed in a lab task, but average drinks per day did not change [3].
  • Three medicines are FDA-approved for alcohol use disorder (naltrexone, acamprosate, disulfiram); GLP-1 drugs are not among them [8].

Do the Wegovy and Zepbound labels say anything about alcohol?

Neither label gives drinking instructions. The Zepbound prescribing information, revised in April 2026, does not discuss alcohol consumption; the only appearance of the word is benzyl alcohol, listed as an inactive ingredient in the injection [1].

The Wegovy label, revised in June 2026, covers the injection and the tablet. In the portions reviewed for this article, which run through the clinical studies section, the word alcohol does not appear. The only use of the word drinking is an instruction to wait before drinking beverages after a tablet [2].

That silence is not the same as a finding of safety. A label reports what was studied and what was reported after approval. It does not say that alcohol is harmless or harmful with the drug, and it leaves the question to the prescriber. What the labels do cover are effects that overlap with what alcohol can do: dehydration from stomach and bowel side effects, low blood sugar with certain diabetes medicines, pancreatitis, and gallbladder disease [1][2]. The sections below take those in turn.

Can GI side effects and dehydration make drinking riskier?

Both labels warn that vomiting and diarrhea can lead to dehydration and kidney injury, and neither label discusses alcohol in that context. Wegovy Section 5.5 describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, most often after gastrointestinal reactions that caused dehydration. It says to monitor kidney function in patients with reactions that could lead to volume depletion, especially when starting or increasing the dose [2]. Zepbound Section 5.3 says the same, noting that most reported events followed nausea, vomiting or diarrhea [1].

The stomach and bowel effects are common. In the Wegovy label's weight-management trials of adults, nausea occurred in 44% of 2,116 people on the 2.4 mg injection versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11% [2]. In Zepbound's weight-reduction trials, nausea was reported by 25% to 29% across three strengths versus 8% on placebo, and vomiting by 8% to 13% versus 2% [1].

Share of adults reporting nausea in each label's weight-management trials (different trials, not a head-to-head comparison)

Source: [1][2] Wegovy label Table 3 [2]; Zepbound label Table 1 [1]. Trial populations and designs differ.

The labels do not say how drinking interacts with these effects, so any link is a clinical judgment rather than a label statement, and a clinician may ask about drinking when someone has persistent nausea or vomiting. The labels' concrete advice is narrower: tell your care team if you cannot keep fluids down, because the main documented danger is volume depletion and kidney injury [1][2].

Does alcohol add to the low blood sugar risk with diabetes medicines?

The labels tie low blood sugar to other diabetes drugs, and separate patient guidance links alcohol to low blood sugar in people who take insulin or certain diabetes medicines. Wegovy Section 5.4 states that the drug lowers blood glucose and can cause hypoglycemia, and it advises considering a lower dose of insulin or an insulin secretagogue when starting [2].

Zepbound Section 5.7 gives numbers from a trial of adults with type 2 diabetes and a BMI of at least 27. Hypoglycemia (plasma glucose under 54 mg/dL) was reported in 4.2% of Zepbound-treated patients versus 1.3% on placebo. Among Zepbound users who also took a sulfonylurea it was 10.3%, versus 2.1% for those who did not [1].

The alcohol link comes from MedlinePlus, the National Library of Medicine's patient service. Its page on diabetes and alcohol (reviewed April 2025) says that if you take insulin or certain types of diabetes medicine, alcohol can cause seriously low blood sugar, that the risk continues for hours after the last drink, and that drinking without eating raises it further. It suggests no more than 1 drink a day for women and 2 for men [10]. That page is general diabetes advice. It does not study GLP-1 drugs, and The Zepbound label also notes hypoglycemia has been reported in adults without type 2 diabetes, so a clinician should assess each person's situation [1].

What do the labels and health agencies say about pancreatitis and the liver?

Both labels warn about pancreatitis and gallbladder disease, and heavy drinking is an independent cause of pancreatitis, so the two concerns overlap. The Wegovy label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists, and that the drug should be stopped if pancreatitis is suspected [2]. Zepbound Section 5.5 carries the same warning, and Section 5.4 says treatment is associated with an increased occurrence of acute gallbladder disease [1]. In Wegovy's trials, cholelithiasis occurred in 1.6% of adults on the injection versus 0.7% on placebo [2].

The National Institute of Diabetes and Digestive and Kidney Diseases lists heavy alcohol use among the most common causes of acute and chronic pancreatitis [12]. The National Institute on Alcohol Abuse and Alcoholism says alcohol misuse over time can lead to pancreatitis, and that heavy drinking can lead to alcohol-associated steatosis, steatohepatitis, hepatitis, fibrosis and cirrhosis [11]. None of these sources says that moderate drinking on a GLP-1 medicine causes pancreatitis. They show two separate risk factors that a clinician may weigh together.

On the liver, the labels are reassuring about drug handling but silent on drinking. Zepbound Section 8.7 recommends no dose adjustment for hepatic impairment, with no change in tirzepatide blood levels in a clinical pharmacology study [1]. The Wegovy label reports that mild, moderate and severe hepatic impairment (Child-Pugh classes A to C) did not produce clinically significant differences in semaglutide levels [2]. Those findings concern how the body processes the drug. They do not address liver injury from alcohol.

Does semaglutide reduce drinking in randomized trials?

Two randomized trials point toward less heavy drinking on semaglutide, but both are small and neither led to an approval. Their participants had an alcohol use disorder, so the results do not apply to people who drink socially.

The first, published in JAMA Psychiatry in 2025, was a phase 2, double-blind trial at a US academic center. Researchers randomized 48 adults with alcohol use disorder who were not seeking treatment, 24 per group, to once-weekly semaglutide or placebo for 9 weeks. Of the participants, 71% were female and the mean age was 39.9 years. Semaglutide reduced grams of alcohol consumed in a laboratory self-administration task (beta -0.48, 95% CI -0.85 to -0.11), drinks per drinking day (beta -0.41, P = .04) and weekly craving (beta -0.39, P = .01). It did not significantly change drinks per calendar day (P = .17) or number of drinking days [3].

Weight fell 5.05% in the semaglutide group versus a 0.18% gain on placebo. The authors report no serious adverse events, no adverse interactions with alcohol and no treatment-related discontinuations. They also note the modest sample, the short duration, a low dose chosen for safety, and that participants drank less than typical treatment-seeking samples. The trial was funded by the National Institute on Alcohol Abuse and Alcoholism [3].

The second, published in The Lancet in 2026, enrolled 108 adults with alcohol use disorder and obesity who were seeking treatment. All were offered cognitive behavioral therapy, and they received weekly semaglutide or placebo for 26 weeks; 88 completed. Heavy drinking days fell in both groups, but significantly more with semaglutide, and blood markers of alcohol intake and liver damage fell more as well. The most common adverse events were mild to moderate gastrointestinal symptoms, and one participant on semaglutide had an adverse event requiring hospitalization [5]. An NIH release described a 41.1% reduction in heavy drinking days on semaglutide, a 13.7% greater reduction than placebo, without specifying whether that margin is relative or absolute [4].

The NIH summary lists clear limits: a small sample, about 18% who did not finish, and enrollment limited to people with obesity, so the findings may not hold for people without it. It also notes that an earlier trial of a GLP-1 drug found no effect on heavy drinking in the group as a whole, with a strong response only in a subset with obesity [4][5]. Funders included the NIH Intramural Research Program and the Novo Nordisk Foundation [5].

What do observational studies report about alcohol outcomes?

Large record reviews associate semaglutide and tirzepatide with fewer alcohol problems, but they cannot prove cause, because people who are prescribed these drugs differ from those who are not. The 2026 study discloses funding by Truveta, and both sets of authors urge caution about causation.

Observational studies of newer GLP-1 medicines and alcohol outcomes
StudyDesign and populationMain findingStated limits
Wang et al., Nature Communications 2024 [6]TriNetX records, 12-month follow-up; semaglutide vs other anti-obesity drugs (n = 83,825 without prior AUD; 4,254 with prior AUD)Hazard ratio 0.50 (95% CI 0.39 to 0.63) for new AUD diagnosis and 0.44 (0.38 to 0.52) for recurrent AUDObservational; residual confounding; dose effects not assessed; authors say results do not justify off-label use for AUD without randomized data
BMJ Open 2026 [7]Truveta records, 40,703 adults with AUD and type 2 diabetes or obesity, 2018 to 2024; semaglutide or tirzepatide vs comparatorsAlcohol-related hospitalization: HR 0.68 (0.54 to 0.85) vs other anti-obesity drugs; HR 0.35 (0.26 to 0.47) vs AUD medicinesResidual confounding; AUD under-recorded; funded by Truveta, with one author employed by Eli Lilly

In the Nature Communications study, the TriNetX network covered 105.3 million patients. The 12-month risk of recurrent AUD was 22.6% with semaglutide versus 43.0% with other anti-obesity drugs in people with a prior diagnosis. The authors state that observational design permits no causal conclusion [6].

The BMJ Open analysis emulated four trials. Its authors flagged a warning sign themselves: in the comparisons against AUD medicines, GLP-1 users also had fewer non-alcohol hospitalizations (HR 0.54 to 0.70), which they read as residual confounding, and more than 80% of comparator patients were censored for stopping treatment. They advise more caution with those two results [7]. The comparisons with other obesity and diabetes drugs were steadier but still observational.

Is any GLP-1 medicine approved for alcohol use disorder?

No. The National Institute on Alcohol Abuse and Alcoholism states that three medications are FDA-approved to help people with alcohol use disorder: naltrexone, acamprosate and disulfiram [8]. The Zepbound label lists weight reduction in adults with obesity or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity, as its uses; alcohol use disorder is not among them [1].

Treatment gaps are large. In 2019 only 1.6% of US adults with alcohol use disorder, about 223,000 of an estimated 14.1 million, used an approved medication, according to a study the National Institutes of Health summarized in 2021 [9]. Researchers and trial authors describe GLP-1 drugs as a candidate for study, not a replacement for proven care. Anyone who is concerned about their drinking can ask a clinician about the approved options, and no one should take a weight-management prescription as treatment for a drinking problem without a clinician's direction.

What this means in practice

  • Do not assume that a label's silence on alcohol means drinking is safe or unsafe. Ask the prescriber how alcohol fits your situation [1][2].
  • Tell your clinician how much you drink before starting, and again if your drinking changes. Heavy drinking and pancreatitis risk are linked independently of any medicine [12].
  • If you also take insulin or a sulfonylurea, ask specifically about low blood sugar, since alcohol can cause it hours after the last drink and the labels link these drugs to hypoglycemia [1][2][10].
  • Seek urgent care for severe, persistent abdominal pain (possibly spreading to the back) or vomiting that prevents you from keeping fluids down, because the labels tie these to pancreatitis and kidney injury [1][2].
  • Treat the alcohol-use-disorder trials as early research in small groups. They are not a reason to use a weight-management drug to treat drinking [3][5][8].
  • If drinking is a problem, three approved medicines and behavioral support exist, and a clinician can discuss them [8][9].

When to talk to a clinician

Raise alcohol with the person who prescribes your medicine whenever you start a GLP-1 drug, change doses, develop vomiting or severe abdominal pain, or notice that your drinking has changed. A clinician can consider your other medicines, your blood sugar, your liver and pancreas history and your goals. Do not stop or change a prescribed medicine on your own.

At Healthy Weight Loss 4 U, every program begins with a clinician evaluation, and that visit is the place to bring up alcohol use, any history of pancreatitis or gallbladder disease, and any diabetes medicines you take. Whether a medication is appropriate for you is a decision for a licensed clinician after that evaluation, and no result is promised.

Frequently asked questions

Can you drink alcohol while taking Wegovy or Zepbound?
The labels do not give a rule about alcohol, so the answer belongs to your prescriber. What the labels do document is dehydration and kidney injury after vomiting or diarrhea, pancreatitis, gallbladder disease, and low blood sugar when combined with some diabetes drugs [1][2]. Tell your clinician how much you drink so they can weigh those points for you.
Does semaglutide reduce alcohol cravings?
In a 9-week randomized trial of 48 adults with alcohol use disorder, weekly craving scores fell more on semaglutide than on placebo (P = .01), but average drinks per day did not change significantly [3]. A 108-person Lancet trial also found less heavy drinking [4][5]. Both are small, and neither means the drug is approved for this use [8].
Is any GLP-1 drug approved to treat alcohol use disorder?
No. The National Institute on Alcohol Abuse and Alcoholism says three medicines are FDA-approved for alcohol use disorder: naltrexone, acamprosate and disulfiram [8]. Zepbound's labeled uses are weight reduction and sleep apnea, not alcohol use disorder [1]. Studies of GLP-1 drugs and drinking are still early, and the authors of the largest observational review ask for randomized trials before off-label use [6].
Can alcohol and GLP-1 medicines both affect pancreatitis risk?
Both labels warn of acute pancreatitis with GLP-1 receptor agonists [1][2], and the NIDDK lists heavy alcohol use as one of the most common causes of acute and chronic pancreatitis [12]. The sources do not say moderate drinking on these drugs causes it. Severe, persistent abdominal pain needs prompt medical attention.
Does alcohol cause low blood sugar with GLP-1 medicines?
The labels link low blood sugar to the drug combined with insulin or sulfonylureas, with Zepbound users reporting 10.3% hypoglycemia with a sulfonylurea versus 2.1% without [1]. MedlinePlus says alcohol can cause seriously low blood sugar for people who take insulin or certain diabetes medicines, for hours after drinking [10]. Ask your clinician what applies to you.
Do observational studies prove GLP-1 drugs lower alcohol problems?
No. A 2024 review of electronic records found a hazard ratio of 0.50 for new alcohol use disorder diagnoses with semaglutide versus other obesity drugs, but its authors stress that observational data allow no causal conclusion [6]. A 2026 BMJ Open study of 40,703 adults showed signs of residual confounding in some comparisons and was funded by Truveta [7].
Are the alcohol study results relevant to people who just have a few drinks?
Probably not directly. The randomized trials enrolled people diagnosed with alcohol use disorder: 48 non-treatment-seeking adults in one and 108 treatment-seeking adults with obesity in the other [3][5]. Their results do not show what happens for occasional drinkers, and the Lancet trial's authors say trials are needed in people without obesity [5].

Sources

  1. ZEPBOUND (tirzepatide) injection, prescribing information (revised 04/2026). U.S. Food and Drug Administration (Drugs@FDA), 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s050lbl.pdf
  2. WEGOVY (semaglutide) injection and tablets, prescribing information (revised 06/2026). Novo Nordisk, 2026. www.novo-pi.com/wegovy.pdf
  3. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (Hendershot et al.). JAMA Psychiatry 82(4):395-405; PMID 39937469; PMC11822619; doi:10.1001/jamapsychiatry.2024.4789, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC11822619/
  4. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking. National Institutes of Health (news release), 2026. www.nih.gov/news-events/news-releases/adding-weekly-glp-1-cognitive-behavioral-therapy-further-reduces-heavy-drinking
  5. GLP-1 plus therapy can reduce heavy drinking (on Klausen et al., Lancet 2026;407:1687-1698, doi:10.1016/S0140-6736(26)00305-3). NIH Research Matters, 2026. nih.gov/news-events/nih-research-matters/glp-1-plus-therapy-can-reduce-heavy-drinking
  6. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population (Wang et al.). Nature Communications 15:4548; doi:10.1038/s41467-024-48780-6, 2024. pmc.ncbi.nlm.nih.gov/articles/PMC11133479
  7. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ Open 16(7):e109259; doi:10.1136/bmjopen-2025-109259, 2026. bmjopen.bmj.com/content/16/7/e109259
  8. FAQs: Searching for Alcohol Treatment. National Institute on Alcohol Abuse and Alcoholism (NIAAA), undated, accessed 2026-10-19. alcoholtreatment.niaaa.nih.gov/FAQs-searching-alcohol-treatment
  9. Few are prescribed medications to treat alcohol problems. NIH Research Matters, 2021. www.nih.gov/news-events/nih-research-matters/few-are-prescribed-medications-treat-alcohol-problems
  10. Diabetes and alcohol (patient instructions, reviewed 4/24/2025). MedlinePlus, National Library of Medicine, 2025. medlineplus.gov/ency/patientinstructions/000968.htm
  11. Alcohol's Effects on the Body. National Institute on Alcohol Abuse and Alcoholism (NIAAA), undated, accessed 2026-10-19. www.niaaa.nih.gov/alcohols-effects-health/alcohols-effects-body
  12. Symptoms and Causes of Pancreatitis. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), undated, accessed 2026-10-19. www.niddk.nih.gov/health-information/digestive-diseases/pancreatitis/symptoms-causes
General information, not medical advice. Results vary and treatment depends on evaluation by a licensed clinician. This article was prepared by the Healthy Weight Loss 4 U Clinical Content Team from the published sources listed above. Nothing here is a recommendation for a specific person, and no treatment is started without an evaluation by a licensed clinician.

Keep reading

Managing GLP-1 Side Effects: Nausea, Reflux, Red Flags

Read →

First 12 Weeks on a GLP-1: What to Expect, Per the Labels

Read →

Semaglutide vs Tirzepatide: What the Trials Show

Read →

Ozempic, Wegovy, Mounjaro, Zepbound: What Each Is FDA-Approved For

Read →

Questions about your own situation? A clinician can review your history and goals. Related: Personalized Weight Loss Counseling.

Book in Lighthouse Point, FL Book in Highlands Ranch, CO